Condition: Catheter Bacteremia · Staphylococcus Aureus Infection · Sponsor: Assistance Publique - Hôpitaux de Paris
The primary objective of the study is to demonstrate, among patients with non-complicated CR-BSIs due to S. aureus, that a single-dose of intravenous (IV) dalbavancin 1500 mg is non-inferior to standard documented antibiotic therapy for 14 days according to national guidelines at DAY 30 (Long follow up visit). As the secondary objectives, the study aims to evaluate according to treatment group: 1. Cure rate at DAY 14 and DAY 90 (EOS); 2. Mortality rate within 90 days of follow-up; 3. Time to negativation of blood cultures; 4. Patient's quality of life; 5. Hospitalization length of stay; 6. Cost-utility analyses; 7. Occurrence of any adverse event (AE and SAE), until Day 90 (EOS).
This description comes directly from the study's public registry record.
Bernard CASTAN, MD · +33 5 53 45 26 00 · bernard.castan@ch-perigueux.fr
Aurélien DINH, MD, PhD · +33 1 47 10 44 32 · aurelien.dinh@aphp.fr
Always discuss trial participation with your own doctor first.
| Infectious Diseases Department, Raymond-Poincaré Hospital - APHP | Garches, France | Not Yet Recruiting |
| Infectious Diseases Department, CH PERIGUEUX | Périgueux, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05117398